UnitedHealth Revenue Grows by $14 billion in 2024
2024年7月16日 · For the second quarter of 2024, UnitedHealth’s earnings reached $98.9 billion, up almost $6 billion from the same quarter last year. The increase, company executives said, reflect growth at Optum and UnitedHealthcare. Second quarter adjusted earnings from operations were $8.7 billion and include business disruption from the Change Healthcare cyberattack.
Understanding “Delinking” in the PBM Legislation | AMCP 2024
2024年4月16日 · Many of the new rules Congress is considering in the still-fluid pharmacy benefit management (PBM) legislation would add reporting requirements to meet transparency goals but wouldn’t fundamentally disrupt the industry’s business practices.
UnitedHealthcare Adds Deductibles to Medicare Part D for 2025
2024年10月3日 · UnitedHealthcare is adding deductibles to Part D prescriptions on certain formulary tiers as a result of plan design changes from the Inflation Reduction Act.
CVS Caremark Makes Changes in Diabetes Coverage for 2025
2024年11月25日 · CVS Caremark has removed several diabetes drugs favor of newer products and generics, and is even favoring an insulin infusion system developed by a company that was cofounded by Alan Lotvin, a former executive at CVS Health.
Aetna Updates MA and Drug Programs for Medicare in 2025
2024年10月1日 · In 2025, Aetna, the health insurance company of CVS Health, has added several new programs to Medicare for 2025. Aetna will launch new Chronic Condition Special Needs Plans (C-SNPs) in Illinois (Chicago) and Pennsylvania (Philadelphia and Pittsburgh).
FDA Approves Attruby for Heart Failure Indication
2024年11月25日 · “Access to this new therapy means more hope and more opportunity to improve the lives of patients with amyloidosis,” Muriel Finkel, president of Amyloidosis Support Groups, a non-profit organization dedicated to the support of amyloidosis patients and caregivers, said in a news release.. Attruby is an oral small molecule stabilizer of transthyretin.
With New Drugs in the Offing, Treatment Cost of ATTR-CM Is …
2024年10月16日 · O’Shea said that the drug spend for ATTR-CM is low at this time because of the disease’s rarity. “But given that, even though utilization is going to be low [and] spend is going to be low, when we look at it in the aggregate of the rare disease category, we're seeing big increases,” O’Shea said.
Premiums for Employer-based Health Insurance Increased by 7
2024年10月9日 · The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.
PTSD - managedhealthcareexecutive.com
Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.
Medicare Star Ratings Could Drop with Focus on Equity | PBMI 2024
2024年9月4日 · The ratings were initially introduced in 2007 to help beneficiaries when choosing plans, and later CMS added financial incentives to reward Medicare Advantage Part C plans that provide high-quality care, Jay Blomquist, pharmacy management consultant, Milliman, said.